Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 179 articles:
HTML format



Single Articles


    September 2020
  1. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220.
    Ann Oncol. 2020 Sep 7. pii: S0923-7534(20)42223.
    PubMed    


    August 2020
  2. LITTON JK, Hurvitz SA, Mina LA, Rugo HS, et al
    Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Ann Oncol. 2020 Aug 20. pii: S0923-7534(20)42106.
    PubMed     Abstract available


  3. MAYER EL, Abramson V, Jankowitz R, Falkson C, et al
    TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
    Ann Oncol. 2020 Aug 13. pii: S0923-7534(20)42061.
    PubMed     Abstract available


    July 2020
  4. LUEN SJ, Asher R, Lee CK, Savas P, et al
    Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39934.
    PubMed     Abstract available


  5. MONTEMURRO F, Delaloge S, Barrios CH, Wuerstlein R, et al
    Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.
    Ann Oncol. 2020 Jul 4. pii: S0923-7534(20)39930.
    PubMed     Abstract available


  6. LYMAN GH, Kuderer NM
    Personalized cancer supportive care in COVID-19 era.
    Ann Oncol. 2020;31:835-837.
    PubMed    


    May 2020
  7. HEIL J, Pfob A
    Patients should be the tipping point of individualizing breast cancer surgery.
    Ann Oncol. 2020 May 28. pii: S0923-7534(20)39844.
    PubMed    


  8. BARCENAS CH, Hurvitz SA, Di Palma JA, Bose R, et al
    Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.
    Ann Oncol. 2020 May 25. pii: S0923-7534(20)39833.
    PubMed     Abstract available


  9. METZGER O, Leone JP, Li T, Tan-Wasielewski Z, et al
    Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
    Ann Oncol. 2020 May 24. pii: S0923-7534(20)39835.
    PubMed     Abstract available


  10. HILBERS FS, Aftimos P
    Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?
    Ann Oncol. 2020 May 15. pii: S0923-7534(20)39818.
    PubMed    


  11. RUGO HS, Andre F, Yamashita T, Cerda H, et al
    Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.
    Ann Oncol. 2020 May 13. pii: S0923-7534(20)39798.
    PubMed     Abstract available


    April 2020
  12. ROSS DS, Liu B, Schram AM, Razavi P, et al
    Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients.
    Ann Oncol. 2020 Apr 26. pii: S0923-7534(20)39306.
    PubMed     Abstract available


  13. CABALLERO C, Piccart M
    Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.
    Ann Oncol. 2020 Apr 25. pii: S0923-7534(20)39307.
    PubMed    


  14. CLEMONS M, Fergusson D, Simos D, Mates M, et al
    A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
    Ann Oncol. 2020 Apr 20. pii: S0923-7534(20)39296.
    PubMed     Abstract available


    March 2020
  15. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 4(rd) International Consensus Guidelines for Breast Cancer in Young Women (BCY4).
    Ann Oncol. 2020 Mar 18. pii: S0923-7534(20)36363.
    PubMed     Abstract available


  16. GRELLETY T, Peyraud F, Sevenet N, Tredan O, et al
    Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
    Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362.
    PubMed    


  17. VAN DONGEN M, Kok M
    Mise en place: towards neoadjuvant chemo-immunotherapy for early triple-negative breast cancer.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36075.
    PubMed    


  18. MURPHY N, Knuppel A, Papadimitriou N, Martin RM, et al
    Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with approximately 430 000 women.
    Ann Oncol. 2020 Mar 9. pii: S0923-7534(20)36019.
    PubMed     Abstract available


  19. MAVROUDIS D, Saloustros E, Malamos N, Kakolyris S, et al
    Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volu
    Ann Oncol. 2020;31:444-445.
    PubMed    


  20. MOSS J, Zick A, Grinshpun A, Carmon E, et al
    Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer.
    Ann Oncol. 2020;31:395-403.
    PubMed     Abstract available


  21. BARROSO-SOUSA R, Jain E, Cohen O, Kim D, et al
    Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Ann Oncol. 2020;31:387-394.
    PubMed     Abstract available


  22. MOSELE F, Stefanovska B, Lusque A, Tran Dien A, et al
    Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Ann Oncol. 2020;31:377-386.
    PubMed     Abstract available


  23. DI COSIMO S, Appierto V, Silvestri M, Ortolan E, et al
    Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast.
    Ann Oncol. 2020;31:435-437.
    PubMed    


    February 2020
  24. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36026.
    PubMed    


  25. ADAMS S, Dieras V, Barrios CH, Winer EP, et al
    Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36038.
    PubMed     Abstract available


  26. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available


  27. SCHMID P, Salgado R, Park YH, Munoz-Couselo E, et al
    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Ann Oncol. 2020 Feb 14. pii: S0923-7534(20)36032.
    PubMed     Abstract available


  28. GRYNBERG M, Mayeur Le Bras A, Hesters L, Gallot V, et al
    First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer.
    Ann Oncol. 2020 Feb 12. pii: S0923-7534(20)35923.
    PubMed    


  29. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.
    Ann Oncol. 2020;31:283-288.
    PubMed     Abstract available


    January 2020
  30. PARK YH, Senkus-Konefka E, Im SA, Pentheroudakis G, et al
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35929.
    PubMed     Abstract available


  31. HEIL J, Kuerer HM, Pfob A, Rauch G, et al
    Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
    Ann Oncol. 2020;31:61-71.
    PubMed     Abstract available


    December 2019
  32. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Abstract available


  33. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Abstract available


  34. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Abstract available


  35. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x3-x11.
    PubMed     Abstract available


  36. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30 Suppl 10:x27-x42.
    PubMed     Abstract available


  37. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x12-x20.
    PubMed     Abstract available


  38. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019;30:2011.
    PubMed    


  39. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple-negative breast cancer and identifies patients with intrinsically good prognosis: have we been bringing owls to Athens?
    Ann Oncol. 2019;30:1849-1850.
    PubMed    


    November 2019
  40. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019;30:1842.
    PubMed    


  41. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019;30:1784-1795.
    PubMed     Abstract available


  42. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Ann Oncol. 2019;30:1776-1783.
    PubMed     Abstract available


  43. BRANDAO M, Coens C, Ignatiadis M
    Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?
    Ann Oncol. 2019;30:1677-1681.
    PubMed    


    October 2019
  44. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple negative breast cancer, and identifies patients with intrinsically good prognosis: Have we been bringing owls to Athens?
    Ann Oncol. 2019 Oct 18. pii: 5593649. doi: 10.1093.
    PubMed    


  45. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019 Oct 8. pii: 5583691. doi: 10.1093.
    PubMed     Abstract available


  46. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019;30:1674.
    PubMed    


  47. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
    Ann Oncol. 2019;30:1541-1557.
    PubMed     Abstract available


  48. ARNEDOS M, Gligorov J
    St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019;30:1533-1535.
    PubMed    


    August 2019
  49. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and Prediction of Benefit from Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen - To Offer More? (aTTom) Trial.
    Ann Oncol. 2019 Aug 28. pii: 5555808. doi: 10.1093.
    PubMed     Abstract available


  50. ARNEDOS M, Gligorov J
    St Gallen international consensus guidelines in early breast cancer: Experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019 Aug 27. pii: 5555359. doi: 10.1093.
    PubMed    


  51. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019 Aug 13. pii: 5549411. doi: 10.1093.
    PubMed    


  52. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548997. doi: 10.1093.
    PubMed    


  53. SRINIVASALU VK, Susan A, Philip A, Jose WM, et al
    147P Clinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543073. doi: 10.1093.
    PubMed    


  54. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.
    Ann Oncol. 2019 Aug 2. pii: 5543097. doi: 10.1093.
    PubMed     Abstract available


  55. SRINIVASALU VK, Susan A, Jose WM, Philip A, et al
    41P Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543072. doi: 10.1093.
    PubMed    


    July 2019
  56. LOI S
    The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.
    Ann Oncol. 2019 Jul 9. pii: 5530161. doi: 10.1093.
    PubMed    


  57. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017".
    Ann Oncol. 2019;30:1181.
    PubMed    


  58. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab".
    Ann Oncol. 2019;30:1180.
    PubMed    


  59. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Corrections to "Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis".
    Ann Oncol. 2019;30:1179.
    PubMed    


  60. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple-negative breast cancer.
    Ann Oncol. 2019;30:1051-1060.
    PubMed     Abstract available


  61. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019;30:1044-1050.
    PubMed     Abstract available


  62. FOULKES WD, Polak P
    Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019;30:1023-1025.
    PubMed    


    June 2019
  63. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 24. pii: 5522519. doi: 10.1093.
    PubMed    


  64. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 4. pii: 5499075. doi: 10.1093.
    PubMed    


    May 2019
  65. OLIVEIRA M, Saura C, Nuciforo P, Calvo I, et al
    FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
    Ann Oncol. 2019 May 30. pii: 5506637. doi: 10.1093.
    PubMed     Abstract available


  66. LOIBL S, Untch M, Burchardi N, Huober J, et al
    A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
    Ann Oncol. 2019 May 16. pii: 5490226. doi: 10.1093.
    PubMed     Abstract available


  67. FOULKES WD, Polak P
    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019 May 15. pii: 5489599. doi: 10.1093.
    PubMed    


  68. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
    Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
    PubMed    


  69. MARSDEN J, Hamoda H
    European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al. (Ann Oncol 2019; 30: doi.org/10.1093/annonc/mdz051).
    Ann Oncol. 2019 May 9. pii: 5482565. doi: 10.1093.
    PubMed    


  70. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple negative breast cancer.
    Ann Oncol. 2019 May 3. pii: 5485241. doi: 10.1093.
    PubMed     Abstract available


  71. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019;30:781-787.
    PubMed     Abstract available


  72. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019;30:774-780.
    PubMed     Abstract available


  73. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019;30:766-773.
    PubMed     Abstract available


    April 2019
  74. DE AZAMBUJA E, Piccart-Gebhart M
    ER+/HER2+ breast cancer: are we really de-escalating?
    Ann Oncol. 2019 Apr 16. pii: 5472336. doi: 10.1093.
    PubMed    


  75. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019 Apr 9. pii: 5435960. doi: 10.1093.
    PubMed     Abstract available


  76. MARRA A, Curigliano G
    T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.
    Ann Oncol. 2019 Apr 2. pii: 5425459. doi: 10.1093.
    PubMed    


  77. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Ann Oncol. 2019;30:567-574.
    PubMed     Abstract available


  78. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019;30:558-566.
    PubMed     Abstract available


    March 2019
  79. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2019 Mar 30. pii: 5423828. doi: 10.1093.
    PubMed    


  80. MESSAOUDENE M, Mourikis TP, Michels J, Fu Y, et al
    T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.
    Ann Oncol. 2019 Mar 29. pii: 5423181. doi: 10.1093.
    PubMed     Abstract available


  81. VEERARAGHAVAN J, De Angelis C, Mao R, Wang T, et al
    A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Ann Oncol. 2019 Mar 23. pii: 5418530. doi: 10.1093.
    PubMed     Abstract available


  82. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019 Mar 19. pii: 5382368. doi: 10.1093.
    PubMed     Abstract available


  83. HREBIEN S, Citi V, Garcia-Murillas I, Cutts R, et al
    Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.
    Ann Oncol. 2019 Mar 12. pii: 5376514. doi: 10.1093.
    PubMed     Abstract available


  84. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019 Mar 12. pii: 5376517. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  85. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019 Feb 23. pii: 5364015. doi: 10.1093.
    PubMed     Abstract available


  86. GUARNERI V, Dieci MV, Bisagni G, Frassoldati A, et al
    De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.
    Ann Oncol. 2019 Feb 18. pii: 5332974. doi: 10.1093.
    PubMed     Abstract available


  87. TELLI ML, Vinayak S
    Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
    Ann Oncol. 2019 Feb 7. pii: 5308591. doi: 10.1093.
    PubMed    


  88. YAP YS, Ho D, Ng RC, Chan CH, et al
    27PDetection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30.
    PubMed    


  89. SON S, Kim H, Shin I
    23PMatricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed    


  90. KIM H, Son S
    22PTherapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed    


  91. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Ann Oncol. 2019;30:236-242.
    PubMed     Abstract available


  92. KIM H, Son S
    Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed    


  93. SON S, Kim H, Shin I
    Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed    


  94. YAP YS, Ho D, Ng RC, Chan CH, et al
    Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30 Suppl 1:i10.
    PubMed    


    January 2019
  95. CONDORELLI R, Mosele F, Verret B, Bachelot T, et al
    Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Ann Oncol. 2019 Jan 31. pii: 5305018. doi: 10.1093.
    PubMed     Abstract available


  96. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019 Jan 23. pii: 5299440. doi: 10.1093.
    PubMed     Abstract available


  97. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.
    Ann Oncol. 2019 Jan 23. pii: 5299438. doi: 10.1093.
    PubMed     Abstract available


  98. DIECI MV, Conte P, Bisagni G, Brandes AA, et al
    Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Ann Oncol. 2019 Jan 17. pii: 5290085. doi: 10.1093.
    PubMed     Abstract available


  99. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
    Ann Oncol. 2019 Jan 9. pii: 5281258. doi: 10.1093.
    PubMed    


  100. BASELGA J, Manikhas A, Cortes J, Llombart A, et al
    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281256. doi: 10.1093.
    PubMed    


  101. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281259. doi: 10.1093.
    PubMed    


  102. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281263. doi: 10.1093.
    PubMed    


  103. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2019 Jan 9. pii: 5281261. doi: 10.1093.
    PubMed    


  104. WU Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, et al
    Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281255. doi: 10.1093.
    PubMed    


    December 2018
  105. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy.
    Ann Oncol. 2018 Dec 27. pii: 5262220. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  106. ADAMS S, Schmid P, Rugo HS, Winer EP, et al
    Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209693. doi: 10.1093.
    PubMed     Abstract available


  107. ADAMS S, Loi S, Toppmeyer D, Cescon DW, et al
    Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209695. doi: 10.1093.
    PubMed     Abstract available


  108. EVRON E, Ben-David AM, Goldberg H, Fried G, et al
    Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer.
    Ann Oncol. 2018 Nov 23. pii: 5200725. doi: 10.1093.
    PubMed     Abstract available


  109. SOKOL ES, Feng YX, Jin DX, Basudan A, et al
    Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Ann Oncol. 2018 Nov 13. pii: 5181087. doi: 10.1093.
    PubMed     Abstract available


  110. FOUKAKIS T
    Carboplatin in the neoadjuvant treatment of triple-negative breast cancer - ready for prime time?
    Ann Oncol. 2018 Nov 5. pii: 5160131. doi: 10.1093.
    PubMed    


    October 2018
  111. MATHEW A, Erqou S
    Can Estrogen Receptor Status Predict for Shorter Duration of Adjuvant Trastuzumab in Early-Stage Breast Cancer?
    Ann Oncol. 2018 Oct 24. pii: 5144112. doi: 10.1093.
    PubMed    


  112. MATIKAS A, Foukakis T, Moebus V, Greil R, et al
    Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients.
    Ann Oncol. 2018 Oct 24. pii: 5144113. doi: 10.1093.
    PubMed     Abstract available


  113. KOK M, Winer E, Loi S
    Passion for Immune checkpoint blockade in triple negative breast cancer? Comment on the IMpassion130 study.
    Ann Oncol. 2018 Oct 23. pii: 5142540. doi: 10.1093.
    PubMed    


  114. COTTU P, D'Hondt V, Dureau S, Lerebours F, et al
    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Ann Oncol. 2018 Oct 11. pii: 5126820. doi: 10.1093.
    PubMed     Abstract available


  115. BRANDAO M, Ignatiadis M
    CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?
    Ann Oncol. 2018 Oct 10. pii: 5126228. doi: 10.1093.
    PubMed    


    September 2018
  116. SZEKELY B, Bossuyt V, Li X, Wali VB, et al
    Immunological differences between primary and metastatic breast cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094494. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  117. CHEN X, Li Y, Ouyang T, Li J, et al
    Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Ann Oncol. 2018 Aug 27. pii: 5079839. doi: 10.1093.
    PubMed     Abstract available


  118. ETTL J, Quek RGW, Lee KH, Rugo HS, et al
    Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ann Oncol. 2018 Aug 15. pii: 5074207. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  119. CARDOSO F, Senkus E, Costa A, Papadopoulos E, et al
    4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
    Ann Oncol. 2018 Jul 19. pii: 5055519. doi: 10.1093.
    PubMed    


  120. ROBSON M
    Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
    Ann Oncol. 2018 Jul 4. pii: 5048958. doi: 10.1093.
    PubMed    


    June 2018
  121. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Abstract available


  122. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2018 Jun 18. pii: 5039891. doi: 10.1093.
    PubMed     Abstract available


  123. ZHANG J, Lin Y, Sun XJ, Wang BY, et al
    Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037891. doi: 10.1093.
    PubMed     Abstract available


  124. IGNATIADIS M, Litiere S, Rothe F, Riethdorf S, et al
    Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.
    Ann Oncol. 2018 Jun 11. pii: 5035683. doi: 10.1093.
    PubMed     Abstract available


  125. MALORNI L, Curigliano G, Minisini AM, Cinieri S, et al
    Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
    Ann Oncol. 2018 Jun 11. pii: 5035682. doi: 10.1093.
    PubMed     Abstract available


  126. YARDLEY DA, Coleman R, Conte P, Cortes J, et al
    nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.
    Ann Oncol. 2018 Jun 6. pii: 5033593. doi: 10.1093.
    PubMed     Abstract available


  127. POGGIO F, Bruzzone M, Ceppi M, Ponde NF, et al
    Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Ann Oncol. 2018 Jun 4. pii: 5026316. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  128. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2018 May 3. pii: 4992289. doi: 10.1093.
    PubMed    


  129. GAGE MM, Mylander WC, Rosman M, Fujii T, et al
    Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Ann Oncol. 2018;29:1280-1285.
    PubMed     Abstract available


  130. LIU C, Wang L, Zhuang J, Liu L, et al
    Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
    Ann Oncol. 2018;29:1329-1330.
    PubMed    


    April 2018
  131. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2018 Apr 27. pii: 4989216. doi: 10.1093.
    PubMed     Abstract available


  132. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2018 Apr 26. pii: 4986930. doi: 10.1093.
    PubMed    


  133. GEFFEN DB
    Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
    Ann Oncol. 2018 Apr 4. pii: 4959909. doi: 10.1093.
    PubMed    


  134. CRUZ C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, et al
    RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.
    Ann Oncol. 2018 Apr 4. pii: 4959904. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  135. CORTES J, Perez-Garcia J, Levy C, Gomez Pardo P, et al
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Ann Oncol. 2018 Feb 21. pii: 4897992. doi: 10.1093.
    PubMed     Abstract available


  136. MARTIN M, Campone M, Bondarenko I, Sakaeva D, et al
    Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Ann Oncol. 2018 Feb 10. pii: 4852792. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  137. TAN WW, Hillman DW, Salim M, Northfelt DW, et al
    N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Ann Oncol. 2018 Jan 29. pii: 4829660. doi: 10.1093.
    PubMed    


  138. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    PubMed     Abstract available


  139. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    PubMed     Abstract available


  140. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    PubMed    


  141. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    PubMed     Abstract available


  142. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    PubMed     Abstract available


  143. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2018 Jan 2. pii: 4782676. doi: 10.1093.
    PubMed    


    December 2017
  144. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Abstract available


  145. SHARMA P, Barlow WE, Godwin AK, Pathak H, et al
    Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313).
    Ann Oncol. 2017 Dec 23. pii: 4774220. doi: 10.1093.
    PubMed     Abstract available


  146. SWAIN SM, Ewer MS, Viale G, Delaloge S, et al
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Ann Oncol. 2017 Dec 15. pii: 4748818. doi: 10.1093.
    PubMed     Abstract available


  147. CONDORELLI R, Spring L, O'Shaughnessy J, Lacroix L, et al
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Ann Oncol. 2017 Dec 11. pii: 4725051. doi: 10.1093.
    PubMed     Abstract available


  148. GENNARI A, Sun Z, Hasler-Strub U, Colleoni M, et al
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Ann Oncol. 2017 Dec 8. pii: 4710349. doi: 10.1093.
    PubMed     Abstract available


  149. PALUCH-SHIMON S, Peccatori FA
    BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
    Ann Oncol. 2017 Dec 5. pii: 4693825. doi: 10.1093.
    PubMed    


    November 2017
  150. FRANCIS PA
    Male Breast Cancer: Pink Ribbon Blues.
    Ann Oncol. 2017 Nov 20. doi: 10.1093.
    PubMed    


  151. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Abstract available


  152. SESTAK I, Smith SG, Howell A, Forbes JF, et al
    Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Ann Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Abstract available


  153. PATEL R, Maxwell S, Yan D, Dressler EV, et al
    Medical Oncologists' Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed    


    October 2017
  154. KOK M
    LAG-3: another brake to release in breast cancer?
    Ann Oncol. 2017 Oct 30. doi: 10.1093.
    PubMed    


  155. CARDOSO F, Bartlett JMS, Slaets L, van Deurzen CHM, et al
    Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Abstract available


  156. BLACKWELL K, Gascon P, Krendyukov A, Gattu S, et al
    Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppr
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Abstract available


  157. CRISCITIELLO C, Bayar MA, Curigliano G, Symmans FW, et al
    A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.
    Ann Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Abstract available


  158. MOBUS V, Jackisch C, Lueck HJ, du Bois A, et al
    Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann Oncol. 2017 Oct 24. doi: 10.1093.
    PubMed     Abstract available


  159. NUCIFORO P, Pascual T, Cortes J, Llombart-Cussac A, et al
    A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Ann Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Abstract available


  160. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


  161. LAMBERTINI M, Goldrat O, Ferreira AR, Dechene J, et al
    Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


  162. FRIBBENS C, Garcia Murillas I, Beaney M, Hrebien S, et al
    Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Ann Oncol. 2017 Oct 4. doi: 10.1093.
    PubMed     Abstract available


  163. FUJII T, Kogawa T, Dong W, Sahin AA, et al
    Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
    Ann Oncol. 2017;28:2420-2428.
    PubMed     Abstract available


    September 2017
  164. HAN HS, Dieras V, Robson M, Palacova M, et al
    Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Abstract available


  165. BURUGU S, Gao D, Leung S, Chia SK, et al
    LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Abstract available


  166. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed    


  167. KIROVA YM, Carroll S, Fourquet A, Offersen B, et al
    The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Ann Oncol. 2017 Sep 22. doi: 10.1093.
    PubMed    


  168. CHAJES V, Assi N, Biessy C, Ferrari P, et al
    A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Abstract available


  169. MESSINA C, Messina M, Zanardi E
    Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed    


  170. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed    


  171. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekl
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Abstract available


  172. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Abstract available


  173. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    PubMed     Abstract available


  174. BERNICHON E, Vallard A, Wang Q, Attignon V, et al
    Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Abstract available


  175. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    PubMed    


    August 2017
  176. CHUNG JH, Pavlick D, Hartmaier R, Schrock AB, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Ann Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  177. PRUNERI G, Lazzeroni M, Bagnardi V, Tiburzio GB, et al
    The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Ann Oncol. 2017;28:321-328.
    PubMed     Abstract available


  178. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Abstract available


  179. MAKKOUK A, Sundaram V, Chester C, Chang S, et al
    Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Ann Oncol. 2017;28:415-420.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: